AstraZeneca (NASDAQ:AZN) reported Phase III OBERON and TITANIA trial results showing tozorakimab reduced moderate and severe COPD exacerbations across broad patient populations while patients remained on standard inhaled treatment.
enGene Therapeutics (NASDAQ:ENGN) reported regulatory and clinical progress for detalimogene, including plans for a U.S. FDA pre-BLA meeting and initiation of a Biologics License Application submission in the fourth quarter of 2026.
Adlai Nortye (NASDAQ:ANL) dosed the first patient in Australia in a global Phase I trial evaluating AN4035, an antibody-drug conjugate designed to treat CEACAM5-enriched RAS-addicted solid tumors.
Bristol Myers Squibb (NYSE:BMY) reported positive Phase 2 QUINTESSENTIAL trial results for arlocabtagene autoleucel (arlo-cel) in adults with quadruple-class exposed relapsed and refractory multiple myeloma.
Pharvaris (NASDAQ:PHVS) reported Phase 3 CHAPTER-3 results showing once-daily oral deucrictibant XR reduced hereditary angioedema attack rates by 83% versus placebo across all HAE types after 24 weeks.
Roivant (NASDAQ:ROIV) reported Phase 2 PHocus trial results showing mosliciguat reduced pulmonary vascular resistance by 56.3% v
Belite Bio (NASDAQ:BLTE) submitted a New Drug Application in Japan for tinlarebant, an investigational once-daily oral therapy for Stargardt disease type 1, under Japan’s Sakigake Designation System.
Beam Therapeutics (NASDAQ:BEAM) reported updated Phase 1/2 data for BEAM-302 showing increased alpha-1 antitrypsin levels and reductions in mutant Z-AAT among patients with alpha-1 antitrypsin deficiency.
Upstream Bio (NASDAQ:UPB) reported Phase 2 VALIANT trial results showing its verekitug treatment reduced annualized asthma exacerbation rates by 56% versus placebo in adults with severe asthma.
Novo Nordisk (NYSE:NVO) reported phase 3 STEP Young trial results showing once-weekly semaglutide plus lifestyle modification reduced BMI more than placebo in 165 children aged 6 to under 12 with obesity after 68 weeks.
Tarsus Pharmaceuticals (NASDAQ:TARS) completed its previously announced acquisition of Alkeus Pharmaceuticals, adding worldwide rights to investigational retinal disease therapy gildeuretinol (ALK-001).
Azenta (NASDAQ:AZTA) received full early repayment of a $35 million secured vendor loan related to the sale of B Medical Systems to Thelema S.à r.l.
